It is also suggested that the traditional dose of anti-VEGF drugs can cause reduced therapeutic antibody uptake in tumors [73], thus emphasizing the importance of appropriate low-dose antiangiogenic therapy in increasing therapeutic efficacy for cancer treatment [74,75]. The gene discussed is VEGFA; the disease is cancer.